NEW YORK, Nov. 8, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing  innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will host a general corporate update and Virtual Roadshow to discuss the current plans for Iomab™-B at 11:00 AM EDT on Monday, November 11, 2013.

The company will discuss the outcome of the recent end of phase two FDA meeting and also the next steps for its Iomab™-B product candidate which is being readied for a pivotal trial.  Iomab™-B has completed several physician sponsored clinical trials examining its potential as a bone marrow conditioning regimen for hematopoietic stem cell transplantation (HSCT) in various blood cancers including a phase I/II study (study 1432) in relapsed and/or refractory elderly acute myeloid leukemia (AML) patients.  The results of study 1432 demonstrated the potential of Iomab™-B to create a new treatment paradigm for HSCT by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HCST; reducing post-transplant complications; and showing a clear survival benefit including curative potential.  

Webcast / Telecast Information:

Date: Monday, November 11, 2013

Time: 11:00 AM EDT

US Dial-in (Toll-free): 1-877-705-6003

International Dial-in: 1-201-493-6725

For the live and archived webcast, please visit the Investors page on the Actinium website at www.actiniumpharmaceuticals.com or https://viavid.webcasts.com/starthere.jsp?ei=1025173

A replay of the call will be available until December 11, 2013. To access the replay, please call 1-877-870-5176 if calling from North America and 1-858-384-5517 if calling from outside the U.S. and Canada. The passcode is 13572657.

About Iomab-B™

Iomab™-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine 131 radioisotope.  BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells.  This  antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM).  When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB), is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Contact:

Media:
Dennis S. Dobson Jr.
Tel:  (203) 258-0159
Email: dennisdobsonjr@dobsonmediagroup.com

Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
Email: csohmer@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.